Kazuya Shimoda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3619363/publications.pdf

Version: 2024-02-01

257450 106344 4,547 131 24 65 citations g-index h-index papers 136 136 136 6731 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene. Nature, 1996, 380, 630-633.	27.8	1,223
2	Integrated molecular analysis of adult T cell leukemia/lymphoma. Nature Genetics, 2015, 47, 1304-1315.	21.4	659
3	Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature, 2016, 534, 402-406.	27.8	536
4	A Common Genetic Polymorphism (46 C to T Substitution) in the 5′-Untranslated Region of the Coagulation Factor XII Gene Is Associated With Low Translation Efficiency and Decrease in Plasma Factor XII Level. Blood, 1998, 91, 2010-2014.	1.4	187
5	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia, 2019, 33, 2867-2883.	7.2	148
6	Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nature Communications, 2014, 5, 3393.	12.8	134
7	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	1.4	124
8	Jaks and stats in cytokine signaling. Stem Cells, 1997, 15, 105-112.	3.2	100
9	Variegated RHOA mutations in adult T-cell leukemia/lymphoma. Blood, 2016, 127, 596-604.	1.4	98
10	The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. Journal of Experimental Medicine, 2016, 213, 1459-1477.	8.5	86
11	Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood, 2015, 125, 304-315.	1.4	67
12	Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood, 2002, 99, 2094-2099.	1.4	63
13	Cutting Edge: Tyk2 Is Required for the Induction and Nuclear Translocation of Daxx Which Regulates IFN-α-Induced Suppression of B Lymphocyte Formation. Journal of Immunology, 2002, 169, 4707-4711.	0.8	54
14	Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leukemia Research, 2005, 29, 761-769.	0.8	53
15	Reduced Tyk2 gene expression in \hat{I}^2 -cells due to natural mutation determines susceptibility to virus-induced diabetes. Nature Communications, 2015, 6, 6748.	12.8	45
16	Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood, 2022, 139, 967-982.	1.4	44
17	Constitutive production of granulocyte colonyâ€stimulating factor and interleukinâ€6 by a human lung cancer cell line, KSNY: Gene amplification and increased mRNA stability. European Journal of Haematology, 1991, 47, 128-133.	2,2	43
18	Cytokine production by peripheral blood monocytes and T cells during haemopoietic recovery after intensive chemotherapy. British Journal of Haematology, 1993, 83, 21-27.	2.5	41

#	Article	IF	CITATIONS
19	Analysis of DNA Methylation in Bowel Lavage Fluid for Detection of Colorectal Cancer. Cancer Prevention Research, 2014, 7, 1002-1010.	1.5	38
20	The Effect of Anabolic Steroids on Anemia in Myelofibrosis with Myeloid Metaplasia: Retrospective Analysis of 39 Patients in Japan. International Journal of Hematology, 2007, 85, 338-343.	1.6	36
21	Ezh2 regulates the Lin28/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells. Experimental Hematology, 2016, 44, 282-296.e3.	0.4	33
22	Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Nature Communications, 2021, 12, 6177.	12.8	30
23	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood, 2020, 136, 698-714.	1.4	28
24	The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. European Journal of Haematology, 2009, 83, 328-333.	2.2	27
25	Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Leukemia, 2021, 35, 454-467.	7.2	27
26	Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. Biochemical and Biophysical Research Communications, 2017, 485, 144-151.	2.1	26
27	Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway. Molecular Nutrition and Food Research, 2015, 59, 2143-2154.	3.3	23
28	ticlopidine-Associated Thrombotic Thrombocytopenic Purpura With an IgG-Type Inhibitor to von Willebrand Factor-Cleaving Protease Activity. International Journal of Hematology, 2001, 74, 347-351.	1.6	21
29	Vitamin D receptor–mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. Blood, 2019, 133, 1619-1629.	1.4	21
30	JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). International Journal of Hematology, 2020, 112, 268-291.	1.6	21
31	The c-kit Molecule and the Surface Immunophenotype of Human Acute Leukemia. Leukemia and Lymphoma, 1994, 14, 421-428.	1.3	18
32	High serum levels of granulocyte-macrophage colony-stimulating factor in patients with liver cirrhosis and granulocytopenia. International Journal of Laboratory Hematology, 2008, 17, 61-63.	0.2	18
33	lκB-ζ Expression Requires Both TYK2/STAT3 Activity and IL-17–Regulated mRNA Stabilization. ImmunoHorizons, 2019, 3, 172-185.	1.8	17
34	Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Advances, 2017, 1, 1001-1015.	5.2	16
35	TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. BMC Cancer, 2020, 20, 5.	2.6	16
36	Oral histone deacetylase inhibitor tucidinostat (<scp>HBI</scp> â€8000) in patients with relapsed or refractory adult Tâ€cell leukemia/lymphoma: Phase <scp>Ilb</scp> results. Cancer Science, 2022, 113, 2778-2787.	3.9	16

3

#	Article	IF	Citations
37	Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis. Blood Cancer Journal, 2019, 9, 42.	6.2	15
38	Effects of mogamulizumab in adult Tâ€cell leukemia/lymphoma in clinical practice. European Journal of Haematology, 2017, 98, 501-507.	2.2	14
39	Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia. International Journal of Hematology, 2018, 108, 411-415.	1.6	14
40	Degradation of p47 by autophagy contributes to CADM1 overexpression in ATLL cells through the activation of NF-κB. Scientific Reports, 2019, 9, 3491.	3.3	14
41	Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. International Journal of Hematology, 2017, 105, 309-317.	1.6	13
42	Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. International Journal of Hematology, 2017, 105, 59-69.	1.6	13
43	Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. International Journal of Hematology, 2018, 107, 681-688.	1.6	13
44	Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells. PLoS ONE, 2021, 16, e0256320.	2.5	13
45	Analysis of the granulocyte colonyâ€stimulating factor receptor gene structure using PCRâ€SSCP in myeloid leukemia and myelodysplastic syndrome. European Journal of Haematology, 1998, 60, 197-201.	2.2	12
46	Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases. Biological and Pharmaceutical Bulletin, 2021, 44, 1585-1592.	1.4	12
47	Impact of TET2 deficiency on iron metabolism in erythroblasts. Experimental Hematology, 2017, 49, 56-67.e5.	0.4	11
48	Essential thrombocytosis attributed to JAK2-T875N germline mutation. International Journal of Hematology, 2019, 110, 584-590.	1.6	11
49	Novel PRMT5-mediated arginine methylations of HSP90A are essential for maintenance of HSP90A function in NDRG2low ATL and various cancer cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118615.	4.1	11
50	Serum Granulocyte Colony-Stimulating Factor Levels in Chronic Neutropenia of Infancy. Pediatric Hematology and Oncology, 1990, 7, 377-381.	0.8	10
51	Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014). Internal Medicine, 2016, 55, 1439-1445.	0.7	10
52	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discovery, 2021, 2, 450-467.	5.0	10
53	Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms. Blood, 2020, 136, 106-118.	1.4	10
54	A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). American Journal of Hematology, 2017, 92, 1324-1332.	4.1	9

#	Article	lF	CITATIONS
55	The mechanism of Tyk2 deficiency-induced immunosuppression in mice involves robust IL-10 production in macrophages. Cytokine, 2020, 130, 155077.	3.2	9
56	Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. Haematologica, 2021, 106, 532-542.	3.5	9
57	CD7-positive acute myeloid leukemia: further evidence of cellular immaturity. Journal of Cancer Research and Clinical Oncology, 1992, 118, 386-388.	2.5	8
58	Analysis of acute myeloid leukemia cells by flow cytometry, introducing a new light-scattering classification. Journal of Cancer Research and Clinical Oncology, 1994, 120, 553-557.	2.5	8
59	Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients. International Journal of Hematology, 2016, 103, 423-428.	1.6	8
60	Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. World Journal of Hepatology, 2017, 9, 1340-1345.	2.0	8
61	Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leukemia and Lymphoma, 2022, 63, 1718-1722.	1.3	8
62	Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. International Journal of Hematology, 2022, 116, 215-227.	1.6	8
63	Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan. International Journal of Hematology, 2012, 96, 342-349.	1.6	7
64	Outcome of allogeneic hematopoietic cell transplantation in patients with adult <scp>T</scp> â€ell leukemia. Hematological Oncology, 2018, 36, 651-655.	1.7	7
65	The regulation of NDRG2 expression during ATLL development after HTLV-1 infection. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2633-2646.	3.8	7
66	Jak1 Plays an Essential Role for Receptor Phosphorylation and Stat Activation in Response to Granulocyte Colony-Stimulating Factor. Blood, 1997, 90, 597-604.	1,4	7
67	Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. International Journal of Hematology, 2022, 115, 208-221.	1.6	7
68	Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult Tâ€cell leukemia/lymphoma. European Journal of Haematology, 2021, 106, 398-407.	2.2	6
69	Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. International Journal of Hematology, 2018, 107, 92-97.	1.6	5
70	Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. Current Medical Research and Opinion, 2018, 34, 531-537.	1.9	5
71	Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-NaÃve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. Blood, 2019, 134, 1663-1663.	1.4	5
72	NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant. Blood, 2010, 116, 4106-4106.	1.4	5

#	Article	IF	Citations
73	Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan. Journal of Clinical Medicine, 2021, 10, 105.	2.4	5
74	Inhibition of adult Tâ€cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis. Cancer Science, 2022, 113, 1406-1416.	3.9	5
75	Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms. Genomics Data, 2015, 4, 102-108.	1.3	4
76	Insufficiency of non-canonical PRC1 synergizes with JAK2V617F in the development of myelofibrosis. Leukemia, 2021, , .	7.2	4
77	Preferential Inhibition of An Activated Form of Janus Kinase 2 (JAK2) by a Novel JAK2 Inhibitor, NS-018. Blood, 2010, 116, 4107-4107.	1.4	4
78	Sequential Organ Failure Assessment (SOFA) score as a prognostic factor for disseminated intravascular coagulation patients with infectious disease treated with recombinant human soluble thrombomodulin (rhTM) in clinical practice. Japanese Journal of Transfusion and Cell Therapy, 2017, 63, 763-779.	0.2	3
79	Monocyte-derived fibrocytes elimination had little contribution on liver fibrosis. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 348-353.	1.3	3
80	Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion. Pharmaceuticals, 2021, 14, 353.	3.8	3
81	A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy. Case Reports in Gastroenterology, 2022, 15, 838-845.	0.6	3
82	Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model Blood, 2009, 114, 3897-3897.	1.4	3
83	Circulating CD34+ cells of primary myelofibrosis patients contribute to myeloid-dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice. International Journal of Hematology, 2022, 115, 198-207.	1.6	3
84	Surrounding Gastric Mucosa Findings Facilitate Diagnosis of Gastric Neoplasm as Gastric Adenoma or Early Gastric Cancer. Gastroenterology Research and Practice, 2016, 2016, 1-5.	1.5	2
85	Acute Liver Failure Due to Severe Hepatic Metastasis of Small-cell Lung Cancer Producing Adrenocorticotropic Hormone Complicating Ectopic Cushing Syndrome. Internal Medicine, 2019, 58, 2977-2982.	0.7	2
86	Single Rectal Neuroendocrine Tumor Associated with Multiple Endocrine Cell Micronests. Internal Medicine, 2020, 59, 619-623.	0.7	2
87	Haploinsufficiency of CALR Confers Hematopoietic Stem Cells (HSCs) with a Clonal Advantage over Wild-Type Cells, and, in Setting of Myeloproliferative Neoplasms, Compensates for the Functions of HSCs Impaired By the Calr Mutation. Blood, 2018, 132, 97-97.	1.4	2
88	NS-018, a Selective JAK2V617F Inhibitor, Improves JAK2V617F-Induced Murine Myelofibrosis Without Decreasing The Erythrocyte Or Platelet Count. Blood, 2013, 122, 3847-3847.	1.4	2
89	Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma. Viruses, 2022, 14, 710.	3.3	2
90	Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With <i>JAK2</i> - or <i>CALR</i> -Mutations. Annals of Laboratory Medicine, 2017, 37, 159-161.	2.5	1

#	Article	IF	Citations
91	Clinical effect of rituximab as early administration for refractory thrombotic thrombocytopenic purpura associated with connective tissue diseases. Modern Rheumatology Case Reports, 2018, 2, 59-67.	0.7	1
92	Three cases of late-onset anthracycline-related cardiomyopathy due to chemotherapies for hematological malignancy. Journal of Echocardiography, 2021, 19, 45-52.	0.8	1
93	Ursodeoxycholic acid markedly promotes the absorption of microemulsionâ€formulated cyclosporine A: A case report. Journal of Clinical Pharmacy and Therapeutics, 2021, , .	1.5	1
94	Abstract 12873: Clonal Hematopoiesis With JAK2V617F Promotes Pulmonary Hypertension Through ALK1. Circulation, 2020, 142, .	1.6	1
95	Mogamulizumab for ATLL in Clinical Practice. Blood, 2016, 128, 2998-2998.	1.4	1
96	Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm. Anticancer Research, 2017, 37, 3841-3847.	1.1	1
97	Uterine relapse of Philadelphia chromosome-negative acute lymphoblastic leukemia. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 103-107.	0.8	1
98	<i>CARD11</i> Mutation Induces Oligoclonal Expansion of T-Cells, and Accelerates ATL Development in Combination with HBZ. Blood, 2020, 136, 17-18.	1.4	1
99	Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas. Blood, 2020, 136, 3-4.	1.4	1
100	The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply. Blood, 2020, 136, 24-25.	1.4	1
101	Secondary Skin Cancer in a Case with Long-term Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Internal Medicine, 2022, , .	0.7	1
102	Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly. Tohoku Journal of Experimental Medicine, 2022, 256, 119-125.	1.2	1
103	Longitudinal changes in an autonomously functioning thyroid nodule with coexisting follicular thyroid carcinoma over 14Âyears. Oxford Medical Case Reports, 2022, 2022, omac041.	0.4	1
104	Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. International Journal of Hematology, 2022, 116, 696-711.	1.6	1
105	CD3 and EBER double positive cells in bone marrow are a diagnostic aid for EBV-positive T-cell lymphoproliferative disorders of childhood. International Cancer Conference Journal, 2012, 1, 33-36.	0.5	0
106	Clinical characteristics of adult T-cell leukemia/lymphoma infiltration in the gastrointestinal tract. BMC Gastroenterology, 2020, 20, 298.	2.0	0
107	Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy. Anticancer Research, 2021, 41, 4127-4131.	1.1	0
108	Fibrocytes in primary myelofibrosis. Oncotarget, 2021, 12, 2101-2103.	1.8	O

#	Article	IF	CITATIONS
109	Transplantation of Primary Human CD34+CD38 - Hematopoietic Stem Cells Recapitulates Idiopathic Myelofibrosis in the NOD/scid/IL2rgKO Mice Blood, 2007, 110, 260-260.	1.4	O
110	Treatment of Idiopathic Myelofibrosis Employing siRNA for Heat Shock Protein 47 (siRNA/HSP47) Encapsulated in Liposomes Blood, 2007, 110, 4646-4646.	1.4	0
111	Elevated Leukocyte Alkaline Phosphatase Scores Induced by Jak2 V617F Mutation. Blood, 2008, 112, 5244-5244.	1.4	0
112	Regulation of p27 by S-Phase Kinase- Associated Protein 2 Is Associated with Aggressiveness in Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2008, 112, 3760-3760.	1.4	0
113	Analysis of Idiopathic Myelofibrosis Initiating Cell in NOD/SCID/IL2rgKO Mice. Blood, 2008, 112, 3715-3715.	1.4	0
114	JAK2V617F Mutation Selectively Exerts the STAT3 Pathway for Enhancing a Neutrophil Activation Marker Blood, 2009, 114, 1901-1901.	1.4	0
115	Absence of Somatically Acquired JAK1 Mutations in Adult T-Cell Leukemia/Lymphoma Blood, 2009, 114, 1921-1921.	1.4	0
116	Potentiated Activation of VLA-4 and VLA-5 Accelerates Proplatelet-Like Formation In Megakaryocytes Blood, 2010, 116, 2585-2585.	1.4	0
117	TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation. Blood, 2011, 118, 2471-2471.	1.4	0
118	Long-Term Cell Autonomous Effect of Tet2 Loss in Hematopoietic Cells in Mice Blood, 2012, 120, 2416-2416.	1.4	0
119	αSMA+ Macrophages Skewed From Hematopoietic Stem Cells By Vitamin D3 Initiate Myelofibrosis and Subsequent Osteosclerosis. Blood, 2013, 122, 340-340.	1.4	0
120	Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma. Blood, 2015, 126, 3882-3882.	1.4	0
121	Physiological Expression of Calr Mutant Increases Cell Growth and Cytokine Independency in Human Cell Lines Expressing Mpl, and Develops Essential Thrombocythemia in Mice. Blood, 2016, 128, 954-954.	1.4	0
122	7. Current Treatment for Leukemia. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 546-551.	0.0	0
123	Mutant calreticulin causes essential thrombocythemia. Oncotarget, 2017, 8, 88251-88252.	1.8	0
124	Insufficiency of Non-Canonical PRC1 Complex Cooperates with an Activating JAK2 Mutation in the Pathogenesis of Myelofibrosis. Blood, 2018, 132, 100-100.	1.4	0
125	TET2 Mutation Associated with Organ Infiltrations in ATLL. Blood, 2018, 132, 1345-1345.	1.4	0
126	Clinical Features and Treatment Outcomes of Hematopoietic Stem Cell Transplantation During 2006-2016 at a Single Institution in Miyazaki Prefecture. Journal of Hematopoietic Cell Transplantation, 2019, 8, 122-134.	0.1	0

#	Article	IF	CITATIONS
127	The Role of Calreticulin in Normal Hematopoiesis and Neoplastic Hematopoiesis of Myeloproliferative Neoplasms. Blood, 2019, 134, 309-309.	1.4	O
128	JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review. Leukemia Research Reports, 2020, 13, 100194.	0.4	0
129	Dissecting Multicellular Ecosystems of HTLV-1 Infection and ATL By Multi-Omics Single Cell Analysis. Blood, 2020, 136, 18-18.	1.4	O
130	Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma. Blood, 2020, 136, 29-30.	1.4	0
131	Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma. Experimental Hematology, 2022, 111, 41-49.	0.4	0